Assessing Revvity (RVTY) Valuation After Signals BioDesign Launch And Earnings Anticipation

Product launch that is drawing fresh attention to Revvity (RVTY)

Revvity (RVTY) recently introduced Signals BioDesign, a cloud native molecular cloning platform aimed at biotech and pharma R&D teams. This launch is helping focus investor attention ahead of the upcoming earnings update.

See our latest analysis for Revvity.

At a share price of $92.90, Revvity has a 7 day share price return of 2.77% and a 30 day share price return of 7.42%. However, its 1 year total shareholder return of 0.63% decline and 3 year total shareholder return of 30.93% decline suggest momentum has been fading over a longer horizon.

If Signals BioDesign has caught your interest in biotech and pharma R&D, it could be a good moment to scan a wider set of healthcare focused AI names through 35 healthcare AI stocks

Revvity’s shares sit at $92.90 with recent short term gains, yet 1 year and 3 year total returns still show declines. Is the stock quietly trading at a discount, or is the market already pricing in future growth?

Most Popular Narrative: 22.3% Undervalued

Revvity’s most followed narrative puts fair value at $119.56, well above the recent $92.90 close, and builds that gap around earnings power and tools demand through 2026.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings, along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Read the complete narrative.

Want to see what sits behind that margin upgrade and higher fair value? The narrative leans on earnings growth, mix shift and a richer future multiple.

Result: Fair Value of $119.56 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still watchpoints, including policy and reimbursement shifts in China, as well as funding pressure on academic and government labs that could challenge this upbeat margin story.

Find out about the key risks to this Revvity narrative.

Another View: Earnings Power Versus Current P/E

The earlier fair value work suggests Revvity could be undervalued by about 31%, but the current P/E of 43.3x is almost double the fair ratio of 22.6x and sits above both peer and North American Life Sciences averages. Is the market overpaying for the earnings recovery story, or is the model too conservative?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and sentiment, this is a moment to move quickly and check the data for yourself. Start with a closer look at 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your style, so keep building a curated watchlist that truly works for you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com